APO Research
Talk to an analyst

APO RESEARCH · REPORT

Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026

29 December 2025217 pages

Choose your research edition.

Industry ResearchFactor Xa Inhibitors Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Factor Xa Inhibitors Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Factor Xa Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Factor Xa Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Factor Xa Inhibitors market include Chia Tai Tianqing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Cspc Ouyi Pharmaceutical, Qilu Pharmaceutical, Nanjing King-Friend Biochemical Pharmaceutical, Kelun Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Shanghai Huilun Pharmaceutical and Hansoh Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Factor Xa Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Factor Xa Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Factor Xa Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Factor Xa Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Factor Xa Inhibitors Segment by Company

Chia Tai Tianqing Pharmaceutical

Zhejiang Hisun Pharmaceutical

Cspc Ouyi Pharmaceutical

Qilu Pharmaceutical

Nanjing King-Friend Biochemical Pharmaceutical

Kelun Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Shanghai Huilun Pharmaceutical

Hansoh Pharma

HEC Pharma

BrightGene

Zydus

Viatris

Pfizer

Lupin

Janssen Pharmaceuticals

GlaxoSmithKline

Eugia Pharma

Dr. Reddy's Laboratories

Daiichi Sankyo

Bristol Myers Squibb

Bayer

Apotex

Accord Healthcare

Factor Xa Inhibitors Segment by Type

Oral Drugs

Injections

Factor Xa Inhibitors Segment by Application

Atrial Fibrillation

Deep Vein Thrombosis

Pulmonary Embolism

Other

Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Factor Xa Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Factor Xa Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Factor Xa Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Factor Xa Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Factor Xa Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Factor Xa Inhibitors industry.

Chapter 3: Detailed analysis of Factor Xa Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Factor Xa Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Factor Xa Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Factor Xa Inhibitors Industry Trends Table 2. Factor Xa Inhibitors Industry Drivers Table 3. Factor Xa Inhibitors Industry Opportunities and Challenges Table 4. Factor Xa Inhibitors Industry Restraints Table 5. Global Factor Xa Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Factor Xa Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Factor Xa Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Factor Xa Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Factor Xa Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Factor Xa Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Factor Xa Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Factor Xa Inhibitors Company, Product Type & Application Table 13. Global Factor Xa Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Factor Xa Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Drugs Table 18. Significant Companies of Injections Table 19. Global Factor Xa Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Factor Xa Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Factor Xa Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Factor Xa Inhibitors Sales Volume Share by Type (2021-2026) Table 23. Global Factor Xa Inhibitors Sales Volume Share by Type (2027-2032) Table 24. Global Factor Xa Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Factor Xa Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Factor Xa Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Factor Xa Inhibitors Sales Value Share by Type (2021-2026) Table 28. Global Factor Xa Inhibitors Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Atrial Fibrillation Table 30. Significant Companies of Deep Vein Thrombosis Table 31. Significant Companies of Pulmonary Embolism Table 32. Significant Companies of Other Table 33. Global Factor Xa Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Factor Xa Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Factor Xa Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Factor Xa Inhibitors Sales Volume Share by Application (2021-2026) Table 37. Global Factor Xa Inhibitors Sales Volume Share by Application (2027-2032) Table 38. Global Factor Xa Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Factor Xa Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Factor Xa Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Factor Xa Inhibitors Sales Value Share by Application (2021-2026) Table 42. Global Factor Xa Inhibitors Sales Value Share by Application (2027-2032) Table 43. Global Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 45. Global Factor Xa Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global Factor Xa Inhibitors Sales by Region (2027-2032) & (K Units) Table 47. Global Factor Xa Inhibitors Sales Market Share by Region (2027-2032) Table 48. Global Factor Xa Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Factor Xa Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Factor Xa Inhibitors Sales Value Share by Region (2021-2026) Table 51. Global Factor Xa Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Factor Xa Inhibitors Sales Value Share by Region (2027-2032) Table 53. Global Factor Xa Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Factor Xa Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Factor Xa Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 58. Global Factor Xa Inhibitors Sales Market Share by Country (2021-2026) Table 59. Global Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 60. Global Factor Xa Inhibitors Sales Market Share by Country (2027-2032) Table 61. Global Factor Xa Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Factor Xa Inhibitors Sales Value Market Share by Country (2021-2026) Table 63. Global Factor Xa Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Factor Xa Inhibitors Sales Value Market Share by Country (2027-2032) Table 65. Chia Tai Tianqing Pharmaceutical Company Information Table 66. Chia Tai Tianqing Pharmaceutical Business Overview Table 67. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 69. Chia Tai Tianqing Pharmaceutical Recent Development Table 70. Zhejiang Hisun Pharmaceutical Company Information Table 71. Zhejiang Hisun Pharmaceutical Business Overview Table 72. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 74. Zhejiang Hisun Pharmaceutical Recent Development Table 75. Cspc Ouyi Pharmaceutical Company Information Table 76. Cspc Ouyi Pharmaceutical Business Overview Table 77. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 79. Cspc Ouyi Pharmaceutical Recent Development Table 80. Qilu Pharmaceutical Company Information Table 81. Qilu Pharmaceutical Business Overview Table 82. Qilu Pharmaceutical Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 84. Qilu Pharmaceutical Recent Development Table 85. Nanjing King-Friend Biochemical Pharmaceutical Company Information Table 86. Nanjing King-Friend Biochemical Pharmaceutical Business Overview Table 87. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 89. Nanjing King-Friend Biochemical Pharmaceutical Recent Development Table 90. Kelun Pharmaceutical Company Information Table 91. Kelun Pharmaceutical Business Overview Table 92. Kelun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 94. Kelun Pharmaceutical Recent Development Table 95. Jiangsu Hengrui Pharmaceuticals Company Information Table 96. Jiangsu Hengrui Pharmaceuticals Business Overview Table 97. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolio Table 99. Jiangsu Hengrui Pharmaceuticals Recent Development Table 100. Shanghai Huilun Pharmaceutical Company Information Table 101. Shanghai Huilun Pharmaceutical Business Overview Table 102. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolio Table 104. Shanghai Huilun Pharmaceutical Recent Development Table 105. Hansoh Pharma Company Information Table 106. Hansoh Pharma Business Overview Table 107. Hansoh Pharma Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Hansoh Pharma Factor Xa Inhibitors Product Portfolio Table 109. Hansoh Pharma Recent Development Table 110. HEC Pharma Company Information Table 111. HEC Pharma Business Overview Table 112. HEC Pharma Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. HEC Pharma Factor Xa Inhibitors Product Portfolio Table 114. HEC Pharma Recent Development Table 115. BrightGene Company Information Table 116. BrightGene Business Overview Table 117. BrightGene Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. BrightGene Factor Xa Inhibitors Product Portfolio Table 119. BrightGene Recent Development Table 120. Zydus Company Information Table 121. Zydus Business Overview Table 122. Zydus Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Zydus Factor Xa Inhibitors Product Portfolio Table 124. Zydus Recent Development Table 125. Viatris Company Information Table 126. Viatris Business Overview Table 127. Viatris Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Viatris Factor Xa Inhibitors Product Portfolio Table 129. Viatris Recent Development Table 130. Pfizer Company Information Table 131. Pfizer Business Overview Table 132. Pfizer Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Pfizer Factor Xa Inhibitors Product Portfolio Table 134. Pfizer Recent Development Table 135. Lupin Company Information Table 136. Lupin Business Overview Table 137. Lupin Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Lupin Factor Xa Inhibitors Product Portfolio Table 139. Lupin Recent Development Table 140. Janssen Pharmaceuticals Company Information Table 141. Janssen Pharmaceuticals Business Overview Table 142. Janssen Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolio Table 144. Janssen Pharmaceuticals Recent Development Table 145. GlaxoSmithKline Company Information Table 146. GlaxoSmithKline Business Overview Table 147. GlaxoSmithKline Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. GlaxoSmithKline Factor Xa Inhibitors Product Portfolio Table 149. GlaxoSmithKline Recent Development Table 150. Eugia Pharma Company Information Table 151. Eugia Pharma Business Overview Table 152. Eugia Pharma Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Eugia Pharma Factor Xa Inhibitors Product Portfolio Table 154. Eugia Pharma Recent Development Table 155. Dr. Reddy's Laboratories Company Information Table 156. Dr. Reddy's Laboratories Business Overview Table 157. Dr. Reddy's Laboratories Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolio Table 159. Dr. Reddy's Laboratories Recent Development Table 160. Daiichi Sankyo Company Information Table 161. Daiichi Sankyo Business Overview Table 162. Daiichi Sankyo Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Daiichi Sankyo Factor Xa Inhibitors Product Portfolio Table 164. Daiichi Sankyo Recent Development Table 165. Bristol Myers Squibb Company Information Table 166. Bristol Myers Squibb Business Overview Table 167. Bristol Myers Squibb Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Bristol Myers Squibb Factor Xa Inhibitors Product Portfolio Table 169. Bristol Myers Squibb Recent Development Table 170. Bayer Company Information Table 171. Bayer Business Overview Table 172. Bayer Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. Bayer Factor Xa Inhibitors Product Portfolio Table 174. Bayer Recent Development Table 175. Apotex Company Information Table 176. Apotex Business Overview Table 177. Apotex Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 178. Apotex Factor Xa Inhibitors Product Portfolio Table 179. Apotex Recent Development Table 180. Accord Healthcare Company Information Table 181. Accord Healthcare Business Overview Table 182. Accord Healthcare Factor Xa Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 183. Accord Healthcare Factor Xa Inhibitors Product Portfolio Table 184. Accord Healthcare Recent Development Table 185. Key Raw Materials Table 186. Raw Materials Key Suppliers Table 187. Factor Xa Inhibitors Distributors List Table 188. Factor Xa Inhibitors Customers List Table 189. Research Programs/Design for This Report Table 190. Authors List of This Report Table 191. Secondary Sources Table 192. Primary Sources List of Figures Figure 1. Factor Xa Inhibitors Product Image Figure 2. Global Factor Xa Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Factor Xa Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Factor Xa Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Drugs Image Figure 10. Injections Image Figure 11. Global Factor Xa Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Factor Xa Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Factor Xa Inhibitors Sales Volume Share by Type (2021-2032) Figure 14. Global Factor Xa Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Factor Xa Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Factor Xa Inhibitors Sales Value Share by Type (2021-2032) Figure 17. Atrial Fibrillation Image Figure 18. Deep Vein Thrombosis Image Figure 19. Pulmonary Embolism Image Figure 20. Other Image Figure 21. Global Factor Xa Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Factor Xa Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Factor Xa Inhibitors Sales Volume Share by Application (2021-2032) Figure 24. Global Factor Xa Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Factor Xa Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Factor Xa Inhibitors Sales Value Share by Application (2021-2032) Figure 27. Global Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Factor Xa Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Factor Xa Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Factor Xa Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 32. North America Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 38. South America Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Factor Xa Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Factor Xa Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Factor Xa Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Factor Xa Inhibitors Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Factor Xa Inhibitors Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Nanjing King-Friend Biochemical Pharmaceutical
  • Kelun Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Shanghai Huilun Pharmaceutical
  • Hansoh Pharma
  • HEC Pharma
  • BrightGene
  • Zydus
  • Viatris
  • Pfizer
  • Lupin
  • Janssen Pharmaceuticals
  • GlaxoSmithKline
  • Eugia Pharma
  • Dr. Reddy's Laboratories
  • Daiichi Sankyo
  • Bristol Myers Squibb
  • Bayer
  • Apotex
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Factor Xa Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Factor Xa Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Factor Xa Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Factor Xa Inhibitors Market Dynamics
  1. 2.1 Factor Xa Inhibitors Industry Trends
  2. 2.2 Factor Xa Inhibitors Industry Drivers
  3. 2.3 Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 2.4 Factor Xa Inhibitors Industry Restraints
3 Factor Xa Inhibitors Market by Company
  1. 3.1 Global Factor Xa Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Factor Xa Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Factor Xa Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Factor Xa Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Factor Xa Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Factor Xa Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Factor Xa Inhibitors Company Product Type and Application
  8. 3.8 Global Factor Xa Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Factor Xa Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Factor Xa Inhibitors Market by Type
  1. 4.1 Factor Xa Inhibitors Type Introduction
  2. 4.1.1 Oral Drugs
  3. 4.1.2 Injections
  4. 4.2 Global Factor Xa Inhibitors Sales Volume by Type
  5. 4.2.1 Global Factor Xa Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Factor Xa Inhibitors Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Factor Xa Inhibitors Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Factor Xa Inhibitors Sales Value by Type
  9. 4.3.1 Global Factor Xa Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Factor Xa Inhibitors Sales Value by Type (2021-2032)
  11. 4.3.3 Global Factor Xa Inhibitors Sales Value Share by Type (2021-2032)
5 Factor Xa Inhibitors Market by Application
  1. 5.1 Factor Xa Inhibitors Application Introduction
  2. 5.1.1 Atrial Fibrillation
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Pulmonary Embolism
  5. 5.1.4 Other
  6. 5.2 Global Factor Xa Inhibitors Sales Volume by Application
  7. 5.2.1 Global Factor Xa Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Factor Xa Inhibitors Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Factor Xa Inhibitors Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Factor Xa Inhibitors Sales Value by Application
  11. 5.3.1 Global Factor Xa Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Factor Xa Inhibitors Sales Value by Application (2021-2032)
  13. 5.3.3 Global Factor Xa Inhibitors Sales Value Share by Application (2021-2032)
6 Factor Xa Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Factor Xa Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Factor Xa Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Factor Xa Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Factor Xa Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Factor Xa Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Factor Xa Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Factor Xa Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Factor Xa Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Factor Xa Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Factor Xa Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Factor Xa Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Factor Xa Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Factor Xa Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Factor Xa Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Factor Xa Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Factor Xa Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Factor Xa Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Factor Xa Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Factor Xa Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Factor Xa Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Factor Xa Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Factor Xa Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Factor Xa Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Factor Xa Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Factor Xa Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Factor Xa Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Zhejiang Hisun Pharmaceutical
  8. 8.2.1 Zhejiang Hisun Pharmaceutical Company Information
  9. 8.2.2 Zhejiang Hisun Pharmaceutical Business Overview
  10. 8.2.3 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  12. 8.2.5 Zhejiang Hisun Pharmaceutical Recent Developments
  13. 8.3 Cspc Ouyi Pharmaceutical
  14. 8.3.1 Cspc Ouyi Pharmaceutical Company Information
  15. 8.3.2 Cspc Ouyi Pharmaceutical Business Overview
  16. 8.3.3 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolio
  18. 8.3.5 Cspc Ouyi Pharmaceutical Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Nanjing King-Friend Biochemical Pharmaceutical
  26. 8.5.1 Nanjing King-Friend Biochemical Pharmaceutical Company Information
  27. 8.5.2 Nanjing King-Friend Biochemical Pharmaceutical Business Overview
  28. 8.5.3 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolio
  30. 8.5.5 Nanjing King-Friend Biochemical Pharmaceutical Recent Developments
  31. 8.6 Kelun Pharmaceutical
  32. 8.6.1 Kelun Pharmaceutical Company Information
  33. 8.6.2 Kelun Pharmaceutical Business Overview
  34. 8.6.3 Kelun Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  36. 8.6.5 Kelun Pharmaceutical Recent Developments
  37. 8.7 Jiangsu Hengrui Pharmaceuticals
  38. 8.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
  39. 8.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  40. 8.7.3 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolio
  42. 8.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  43. 8.8 Shanghai Huilun Pharmaceutical
  44. 8.8.1 Shanghai Huilun Pharmaceutical Company Information
  45. 8.8.2 Shanghai Huilun Pharmaceutical Business Overview
  46. 8.8.3 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolio
  48. 8.8.5 Shanghai Huilun Pharmaceutical Recent Developments
  49. 8.9 Hansoh Pharma
  50. 8.9.1 Hansoh Pharma Company Information
  51. 8.9.2 Hansoh Pharma Business Overview
  52. 8.9.3 Hansoh Pharma Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hansoh Pharma Factor Xa Inhibitors Product Portfolio
  54. 8.9.5 Hansoh Pharma Recent Developments
  55. 8.10 HEC Pharma
  56. 8.10.1 HEC Pharma Company Information
  57. 8.10.2 HEC Pharma Business Overview
  58. 8.10.3 HEC Pharma Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 HEC Pharma Factor Xa Inhibitors Product Portfolio
  60. 8.10.5 HEC Pharma Recent Developments
  61. 8.11 BrightGene
  62. 8.11.1 BrightGene Company Information
  63. 8.11.2 BrightGene Business Overview
  64. 8.11.3 BrightGene Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 BrightGene Factor Xa Inhibitors Product Portfolio
  66. 8.11.5 BrightGene Recent Developments
  67. 8.12 Zydus
  68. 8.12.1 Zydus Company Information
  69. 8.12.2 Zydus Business Overview
  70. 8.12.3 Zydus Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zydus Factor Xa Inhibitors Product Portfolio
  72. 8.12.5 Zydus Recent Developments
  73. 8.13 Viatris
  74. 8.13.1 Viatris Company Information
  75. 8.13.2 Viatris Business Overview
  76. 8.13.3 Viatris Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Viatris Factor Xa Inhibitors Product Portfolio
  78. 8.13.5 Viatris Recent Developments
  79. 8.14 Pfizer
  80. 8.14.1 Pfizer Company Information
  81. 8.14.2 Pfizer Business Overview
  82. 8.14.3 Pfizer Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Pfizer Factor Xa Inhibitors Product Portfolio
  84. 8.14.5 Pfizer Recent Developments
  85. 8.15 Lupin
  86. 8.15.1 Lupin Company Information
  87. 8.15.2 Lupin Business Overview
  88. 8.15.3 Lupin Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Lupin Factor Xa Inhibitors Product Portfolio
  90. 8.15.5 Lupin Recent Developments
  91. 8.16 Janssen Pharmaceuticals
  92. 8.16.1 Janssen Pharmaceuticals Company Information
  93. 8.16.2 Janssen Pharmaceuticals Business Overview
  94. 8.16.3 Janssen Pharmaceuticals Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolio
  96. 8.16.5 Janssen Pharmaceuticals Recent Developments
  97. 8.17 GlaxoSmithKline
  98. 8.17.1 GlaxoSmithKline Company Information
  99. 8.17.2 GlaxoSmithKline Business Overview
  100. 8.17.3 GlaxoSmithKline Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 GlaxoSmithKline Factor Xa Inhibitors Product Portfolio
  102. 8.17.5 GlaxoSmithKline Recent Developments
  103. 8.18 Eugia Pharma
  104. 8.18.1 Eugia Pharma Company Information
  105. 8.18.2 Eugia Pharma Business Overview
  106. 8.18.3 Eugia Pharma Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Eugia Pharma Factor Xa Inhibitors Product Portfolio
  108. 8.18.5 Eugia Pharma Recent Developments
  109. 8.19 Dr. Reddy's Laboratories
  110. 8.19.1 Dr. Reddy's Laboratories Company Information
  111. 8.19.2 Dr. Reddy's Laboratories Business Overview
  112. 8.19.3 Dr. Reddy's Laboratories Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolio
  114. 8.19.5 Dr. Reddy's Laboratories Recent Developments
  115. 8.20 Daiichi Sankyo
  116. 8.20.1 Daiichi Sankyo Company Information
  117. 8.20.2 Daiichi Sankyo Business Overview
  118. 8.20.3 Daiichi Sankyo Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Daiichi Sankyo Factor Xa Inhibitors Product Portfolio
  120. 8.20.5 Daiichi Sankyo Recent Developments
  121. 8.21 Bristol Myers Squibb
  122. 8.21.1 Bristol Myers Squibb Company Information
  123. 8.21.2 Bristol Myers Squibb Business Overview
  124. 8.21.3 Bristol Myers Squibb Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Bristol Myers Squibb Factor Xa Inhibitors Product Portfolio
  126. 8.21.5 Bristol Myers Squibb Recent Developments
  127. 8.22 Bayer
  128. 8.22.1 Bayer Company Information
  129. 8.22.2 Bayer Business Overview
  130. 8.22.3 Bayer Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Bayer Factor Xa Inhibitors Product Portfolio
  132. 8.22.5 Bayer Recent Developments
  133. 8.23 Apotex
  134. 8.23.1 Apotex Company Information
  135. 8.23.2 Apotex Business Overview
  136. 8.23.3 Apotex Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Apotex Factor Xa Inhibitors Product Portfolio
  138. 8.23.5 Apotex Recent Developments
  139. 8.24 Accord Healthcare
  140. 8.24.1 Accord Healthcare Company Information
  141. 8.24.2 Accord Healthcare Business Overview
  142. 8.24.3 Accord Healthcare Factor Xa Inhibitors Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Accord Healthcare Factor Xa Inhibitors Product Portfolio
  144. 8.24.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Factor Xa Inhibitors Value Chain Analysis
  2. 9.1.1 Factor Xa Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Factor Xa Inhibitors Sales Mode & Process
  6. 9.2 Factor Xa Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Factor Xa Inhibitors Distributors
  9. 9.2.3 Factor Xa Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst